ArticleBMC cancer2015

Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients.

Eiji Suzuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.